Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (5513)	10/18/1998 6:06:00 PM
From: Clive Roberts	Read Replies (2) \| Respond to of 6136

A little off subject but I guess relevant to Agouron's cancer pipeline. Richard...I met with someone connected to KCAP two weeks ago when the stock was around 50 cents......it's gone to $3 during that time! Should have thought more of the tip! One of the reasons is they've purchased some kind of Internet 'club' company....the other is their involvement with Crystal Recovery Systems a new cancer treatment. Obvious synergies here! Comments? Key Capital Corporation Announces Exclusive 504 Offering for Cancer Project LAWRENCEVILLE, Ga.--(BUSINESS WIRE)--May 20, 1998--Key Capital Corporation (OTC BB:KCAP - news) announces that it has negotiated the right for an exclusive seed share offering to all Key Capital Corporation shareholders. The offering is for shares in Crystal Recovery Systems, Inc. which has a 50% interest in the international commercialization rights to a Cancer treatment which, in Phase 1 trials on 100 human patients with diverse Cancers, achieved an astounding overall response of 41%. The test patients were all regarded as terminal or non-treatable by current available treatment. A new laboratory is currently being established in Colorado where the next batch of the immune adjuvants and biologic response modifiers to be used in further human trials will be made. The laboratory is expected to be completed within the next 60 days. Given the recent extensive press coverage of the various developments in the area of cancer research and cancer drug and treatment advancements, Key Capital Corporation is excited to offer this exclusive opportunity for its shareholders to participate in this ''seed'' offering for a cancer treatment which has, to date, demonstrated extra-ordinary success in human trials. Any Key Capital Shareholder holding at least 2,000 Key Capital Corporation shares as of June 30, 1998 is eligible to participate in the Crystal Recovery Systems, Inc. 504 Offering. The minimum subscription is for 2,000 shares at $1.25 per share and the maximum is for 10,000 shares per shareholder. There are two Warrants attached to each share, the first exercisable at $3.00 on or before June 30,1999 and the second at $5.00 on or before June 30, 2000. Only 400,000 Shares are being offered and will be issued on a first come basis. An Offering Memorandum can be obtained from the company by calling 1 888 823 5767 or from the Company website at: www.kcap.net as from May 23, 1998. Key Capital Corporation is an Investment Banking and Management Group and has a 10% shareholding interest in its client company Crystal Recovery Systems, Inc. NOTE: The information contained in this release, other than historical information, may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Projections and other forward-looking statements and management expectations regarding future events and/or financial performance of the company - although given in good faith - are inherently uncertain and actual events or results may differ materially. Contact: Key Capital Corporation Investor Relations, 888/823-5767 www.kcap.net